Novo Nordisk/X
Aug 2, 2025, 03:50
FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
Novo Nordisk US has shared a proud post on X:
“PRESS: Novo Nordisk receives US FDA approval for a new indication for a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. ”
To learn more, follow the link.
Stay informed with Hemostasis Today.
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning
-
Oct 9, 2026, 14:07Chokri Ben Lamine: Pain After Allogeneic Stem Cell Transplantation in Sickle Cell Disease